Concepedia

The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study

Gregory C McDermott, Xiaoqing Fu, Claire Cook, Catherine Ahola, Brett Doliner, Jennifer S. Hanberg, John H. Stone, Hyon K. Choi, Yuqing Zhang, Zachary S. Wallace

Annals of the Rheumatic Diseases · 2022 · 17 citations · 32 references

DOIFull text

Open access

Concepts

References

32

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

Mary E. Charlson, Peter Pompei, Kathy L. Aleš et al. · Journal of Chronic Diseases · 1987 · 49.9K citations

, , +15

Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.

Miguel A. Hernán, James M. Robins · American Journal of Epidemiology · 2016 · 2.7K citations · Full text

, , +16

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

John H. Stone, Peter A. Merkel, Robert Spiera et al. · New England Journal of Medicine · 2010 · 2.7K citations · Full text

, , +17

AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSIS

Fokko J. van der Woude, S. Lobatto, H. Permin et al. · The Lancet · 1985 · 1.9K citations

, , +12

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

Rachel Jones, Jan Willem Cohen Tervaert, Thomas Häuser et al. · New England Journal of Medicine · 2010 · 1.7K citations · Full text

, , +14